Teriparatide prevents fractures in osteoporosis; healing data are thin

How does teriparatide work?

Teriparatide is recombinant human parathyroid hormone (amino acids 1-34), given as a daily subcutaneous injection, and its bone-building effect depends on that pulsed dosing pattern.

Continuous PTH exposure, as in hyperparathyroidism, is net catabolic and breaks down bone. Brief daily pulses preferentially stimulate osteoblast activity over osteoclast activity through the PTH1 receptor, producing a net anabolic effect on bone mass. That well-characterized pharmacology underlies every fracture-risk trial cited below.

An anabolic mechanism does not automatically mean teriparatide speeds the repair of a specific fracture. Systemic fracture prevention and repair of an existing fracture are different outcomes, and evidence for one does not establish the other. Both are plausible from the same receptor biology. Only fracture prevention is established by trial-grade human evidence.

Does teriparatide prevent fractures in osteoporosis?

Yes. Teriparatide reduces new fractures in people with osteoporosis, shown in adequately sized randomized trials against placebo or an active comparator.

The VERO trial randomized postmenopausal women with severe osteoporosis to teriparatide or risedronate for 24 months, with new radiographic vertebral fracture as the primary outcome. New vertebral fractures occurred in 5.4% of the teriparatide group versus 12.0% of the risedronate group (risk ratio 0.44, 95% CI 0.29-0.68). Clinical fractures, a composite of non-vertebral and symptomatic vertebral fractures, were also lower with teriparatide: 4.8% versus 9.8% ^[9].

A 2025 network meta-analysis pooling teriparatide and abaloparatide trials against placebo confirmed that both agents reduce vertebral and non-vertebral fracture ^[1]. A UK health technology assessment found teriparatide effective relative to no treatment and to other non-bisphosphonate options across a systematic fracture and bone density review ^[2].

Incident fracture reduction in people with osteoporosis is the layer of evidence that deserves the word "proven."

Does teriparatide speed healing of a broken bone?

Trial-grade evidence has not established that teriparatide speeds healing of an existing fracture. Peptide-focused content borrows that claim directly from the prevention data, and the claim does not hold up under the same scrutiny.

None of the randomized, controlled human trials cited below set out to test whether teriparatide shortens time to clinical union or accelerates functional recovery after an acute fracture. The healing evidence is thin, inconsistent, and mostly outside the trial-grade record, although small distal radius and hip fracture healing trials exist in the broader literature.

Why doesn't fracture-prevention evidence prove faster healing?

Teriparatide's fracture-prevention trials and fracture-healing studies measure different endpoints. Prevention trials count new fractures over many months in people who do not yet have the fracture being studied.

Healing research tracks callus maturation or time to union in someone who already has a break. Coverage that cites Neer-type prevention data to support a healing-acceleration claim is applying the right drug to the wrong endpoint.

A 2024 network meta-analysis of conservative treatments for pain after acute vertebral compression fracture shows the same distinction from another angle. It treated pain and functional recovery as outcomes distinct from bone mineral density or fracture incidence, and evaluated agents such as calcitonin and NSAIDs against that separate endpoint ^[3]. A literature built around pain and function as their own measurable outcomes underscores the point the healing claim blurs: imaging and density changes are not interchangeable with clinical recovery. For calcitonin itself, see calcitonin's regulatory history.

How is teriparatide dosed in the trials?

The VERO trial dosed teriparatide at 20 μg daily by subcutaneous injection for 24 months against its comparator ^[9].

That schedule matches the daily-injection, roughly two-year treatment window of most of the pivotal osteoporosis trials cited below. Abaloparatide, a related PTH1 receptor agonist, was tested at 80 μg daily over 18 months in its pivotal placebo-controlled trial, with teriparatide included as an open-label comparator arm ^[8].

How does teriparatide compare with abaloparatide and romosozumab?

Abaloparatide showed somewhat better non-vertebral and hip fracture odds than teriparatide, and romosozumab produced larger bone density gains, but none of those comparisons measures healing speed.

In the 2025 network meta-analysis, abaloparatide showed somewhat better odds than teriparatide against non-vertebral and hip fracture specifically (OR 0.87 and 0.81) ^[1]. The injectable abaloparatide evidence covers that drug in detail.

Romosozumab, a sclerostin-inhibiting monoclonal antibody with a different mechanism, produced significantly larger lumbar spine bone density gains than teriparatide across pooled randomized trials. Romosozumab's mean difference was 13.18 versus placebo, compared with teriparatide's smaller placebo-adjusted gain, and the mean difference was 4.35 in favor of romosozumab directly over teriparatide ^[4]. A separate meta-analysis of romosozumab trials in vertebral compression fracture also used teriparatide as one of the active comparators ^[7].

All of these comparisons use bone density and new-fracture-incidence endpoints.

Does teriparatide work in chronic kidney disease?

Pooled trial data show lower vertebral fracture risk with anti-osteoporotic agents, including teriparatide, in chronic kidney disease stages 1 through 3, but no significant reduction in stages 4 and 5 ^[5].

A Cochrane review scoped to CKD stages 3 through 5D was designed to assess whether standard osteoporosis pharmacotherapy is both effective and safe in that altered mineral-metabolism setting ^[6]. Kidney function is a real boundary on how far teriparatide's fracture evidence generalizes.

Why did teriparatide carry a cancer warning?

Teriparatide's osteosarcoma boxed warning traced to rodent data. The boxed warning was removed from the US label in 2020 after post-marketing surveillance.

What is still unknown about teriparatide and fracture healing?

Teriparatide's effect on the repair of an existing break is the open question: faster healing is mechanistically plausible and unproven by trial-grade human data.

None of the randomized controlled trials cited below uses time to clinical union, return of weight-bearing function, or a comparable functional recovery measure as a primary endpoint in people who already have an acute fracture. Teriparatide's proven benefit is a lower risk of the next fracture, not faster repair of the current one.